SPAC Takes Anew Path, Pivoting From Energy Storage To Merge With Alzheimer’s Gene Therapy Biotech

By merging with a blank check company, Anew Medical plans to land a Nasdaq listing and $54 million in cash to fund the development of its neurodegenerative disease gene therapies, provided investors don’t pull their money before the deal closes.